BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Innovent Biologics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Innovent Biologics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07122687-2254@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:IBI363: Phase 2 readout est. (NCT07122687)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 C
 ombined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as N
 eoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07122687
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797297-2254@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 2 readout est. (NCT06797297)
DESCRIPTION:IBI363\, phase 2.\nStudy: A Study to Evaluate the Efficacy and 
 Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Un
 resectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Ha
 d Not Previously Received Systemic Therapy\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibi
 363#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06797297
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402070-2254@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 2 readout est. (NCT07402070)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 a
 s Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cance
 r\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07402070
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764861-3193@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI3003: Phase 2 readout est. (NCT07764861)
DESCRIPTION:IBI3003\, phase 2\, Multiple Myeloma.\nStudy: A Open-Label Phas
 e in Participants With Multiple Myeloma\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibi300
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 764861
URL:https://assetmemo.bio/drug/ibi3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884293-183@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:mazdutide: Phase 3 readout est. (NCT06884293)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study Comparing IBI362
  vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfu
 nction-associated Fatty Liver Disease （MAFLD）\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/mazdutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06884293
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640361-2925@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06640361)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 SDH-deficient GIST.\nEstimated primary completion: 31 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06640361
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793478-2836@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Quizartinib: Phase 1/2 readout est. (NCT03793478)
DESCRIPTION:Quizartinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Safet
 y and Efficacy of Quizartinib in Children and Young Adults With Acute Myel
 oid Leukemia (AML)\, a Cancer of the Blood\nEstimated primary completion: 
 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/quizartin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3793478
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931028-183@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270507
DTEND;VALUE=DATE:20270508
SUMMARY:mazdutide: Phase 3 readout est. (NCT06931028)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2\nEstimated p
 rimary completion: 7 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/mazdutide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06931028
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612137-1995@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sintilimab: Phase 1/2 readout est. (NCT07612137)
DESCRIPTION:Sintilimab\, phase 1/2.\nStudy: Study of IBI3005 Combination Th
 erapy in Participants With Unresectable\, Locally Advanced or Metastatic S
 olid Tumors\nEstimated primary completion: 30 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07612137
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423911-2925@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06423911)
DESCRIPTION:Olverembatinib\, phase 3\, Chronic Myeloid Leukemia.\nStudy: St
 udy of Olverembatinib (HQP1351) in Patients With CML-CP\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06423911
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-183@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:mazdutide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:mazdutide\, phase 2\, Obesity.\nStudy: A Master Protocol Study 
 (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Pa
 rticipants With Obesity or Overweight\nEstimated primary completion: Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mazdutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614
 3956
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3355@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Pegenzileukin: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Pegenzileukin\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuxima
 b in Combination With Novel Agents in RRMM - Master Protocol\nEstimated pr
 imary completion: 13 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pegenzileukin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/pegenzileukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255209-183@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:mazdutide: Phase 3 readout est. (NCT07255209)
DESCRIPTION:mazdutide\, phase 3\, Obesity.\nStudy: A Study of IBI362 in Chi
 nese Adolescents With Obesity or Overweight\nEstimated primary completion:
  31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maz
 dutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07255209
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109531-7622@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Limertinib: Phase 3 readout est. (NCT07109531)
DESCRIPTION:Limertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC
 202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatme
 nt of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpr
 ession After Failure of EGFR-TKI Therapy\nEstimated primary completion: 31
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07109531
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-1995@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: A Study to Evaluate the Efficac
 y and Safety of IBI310 and Sintilimab Combination Therapy in Patients With
  Hepatocellular Carcinoma as First-line Treatment.\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07490262
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051409-2925@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06051409)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06051409
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824168-2836@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Quizartinib: Phase 2 readout est. (NCT06824168)
DESCRIPTION:Quizartinib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Evaluat
 ion of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute
  Myeloid Leukemia Patients in Complete Remission\nEstimated primary comple
 tion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 izartinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06824168
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2925@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Olverembatinib: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Olverembatinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: St
 udy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in
  Patients Relapsed/Refractory AML\nEstimated primary completion: September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/olverembatinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045
 01120
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081920-2254@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20281019
DTEND;VALUE=DATE:20281020
SUMMARY:IBI363: Phase 2 readout est. (NCT06081920)
DESCRIPTION:IBI363\, phase 2.\nStudy: A Study of IBI363 in Subjects With Ad
 vanced Melanoma\nEstimated primary completion: 19 October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06081920
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722494-2254@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:IBI363: Phase 3 readout est. (NCT07722494)
DESCRIPTION:IBI363\, phase 3\, Colorectal Cancer.\nStudy: IBI363 Combined W
 ith Bevacizumab for Advanced Colorectal Cancer\nEstimated primary completi
 on: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ibi363#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07722494
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217301-2254@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:IBI363: Phase 3 readout est. (NCT07217301)
DESCRIPTION:IBI363\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
 \nEstimated primary completion: 1 November 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07217301
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564324-2075@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT06564324)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Pos
 itive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients\n
 Estimated primary completion: January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/taletrectinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06564324
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352969-533@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:IBI3016: Phase 2 readout est. (NCT07352969)
DESCRIPTION:IBI3016\, phase 2\, Hypertension.\nStudy: A Dose Finding Study 
 of IBI3016 in Mild to Moderate Hypertensive Patients\nEstimated primary co
 mpletion: 27 March 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ibi3016#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07352969
URL:https://assetmemo.bio/drug/ibi3016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623798-3193@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:IBI3003: Phase 3 readout est. (NCT07623798)
DESCRIPTION:IBI3003\, phase 3\, Multiple Myeloma.\nStudy: A Study in Partic
 ipants With Relapsed or Refractory Multiple Myeloma for IBI3003\nEstimated
  primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ibi3003#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07623798
URL:https://assetmemo.bio/drug/ibi3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07295509-39@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:picankibart: Phase 2/3 readout est. (NCT07295509)
DESCRIPTION:picankibart\, phase 2/3.\nStudy: A Study of Picankibart in Pati
 ents With Active Psoriatic Arthritis\nEstimated primary completion: 31 Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/picankiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7295509
URL:https://assetmemo.bio/drug/picankibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917468-1995@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20300325
DTEND;VALUE=DATE:20300326
SUMMARY:Sintilimab: Phase 3 readout est. (NCT07917468)
DESCRIPTION:Sintilimab\, phase 3.\nStudy: Sintilimab Combined With LCCRT Fo
 llowed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Ca
 ncer\nEstimated primary completion: 25 March 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07917468
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578247-2836@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20300626
DTEND;VALUE=DATE:20300627
SUMMARY:Quizartinib: Phase 3 readout est. (NCT06578247)
DESCRIPTION:Quizartinib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Quizart
 inib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-IT
 D Negative AML\nEstimated primary completion: 26 June 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/quizartinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06578247
URL:https://assetmemo.bio/drug/quizartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483567-1995@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07483567)
DESCRIPTION:Sintilimab\, phase 2.\nStudy: IBI343 in Combination With Sintil
 imab and SOX Regimen for Perioperative Treatment of Resectable\, Locally A
 dvanced Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated pri
 mary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07483567
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154706-2075@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT07154706)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Po
 sitive NSCLC (TRUST-IV)\nEstimated primary completion: 30 August 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/taletrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07154706
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897188-7622@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Limertinib: Phase 3 readout est. (NCT07897188)
DESCRIPTION:Limertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC
 202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET
 + Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 30 D
 ecember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limerti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07897188
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862998-2225@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20310225
DTEND;VALUE=DATE:20310226
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07862998)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants
  With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Wi
 th FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic 
 Therapy\nEstimated primary completion: 25 February 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07862998
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643623-1995@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Sintilimab: Phase 2/3 readout est. (NCT07643623)
DESCRIPTION:Sintilimab\, phase 2/3.\nStudy: Neoadjuvant and Adjuvant Therap
 y Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimu
 mab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma\nEs
 timated primary completion: 31 December 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07643623
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
